Adaptimmune Therapeutics Newsroom

Adaptimmune Therapeutics Analyst Ratings

BenzingaNov 19 12:43 ET

H.C. Wainwright Maintains Adaptimmune Therapeutics(ADAP.US) With Buy Rating, Maintains Target Price $3.5

Moomoo NewsNov 19 10:32 ET

Promising Future for Adaptimmune Therapeutics: Buy Rating Supported by Breakthrough Therapies and Strong Financial Position

TipRanksNov 19 09:37 ET

Analysts' Opinions Are Mixed on These Healthcare Stocks: Adaptimmune Therapeutics (ADAP), Fulcrum Therapeutics (FULC) and Immunic (IMUX)

TipRanksNov 19 02:26 ET

Adaptimmune Therapeutics Is Maintained at Buy by Guggenheim

Dow JonesNov 15 14:12 ET

Wells Fargo Maintains Adaptimmune Therapeutics(ADAP.US) With Hold Rating, Maintains Target Price $2

Moomoo NewsNov 15 06:32 ET

Scotiabank Maintains Adaptimmune Therapeutics(ADAP.US) With Buy Rating, Maintains Target Price $3.15

Moomoo NewsNov 14 08:35 ET

TD Cowen Maintains Adaptimmune Therapeutics(ADAP.US) With Buy Rating

Moomoo NewsNov 14 08:35 ET

Adaptimmune Therapeutics: Solid Financials and Strategic Advancements Prompt Buy Rating

TipRanksNov 14 08:12 ET

Scotiabank Remains a Buy on Adaptimmune Therapeutics (ADAP)

TipRanksNov 14 07:39 ET

H.C. Wainwright Maintains Adaptimmune Therapeutics(ADAP.US) With Buy Rating, Cuts Target Price to $3.5

Moomoo NewsNov 14 06:32 ET

H.C. Wainwright Maintains Adaptimmune Therapeutics(ADAP.US) With Buy Rating, Maintains Target Price $4

Moomoo NewsAug 14 05:35 ET

Adaptimmune Therapeutics Analyst Ratings

BenzingaAug 13 14:02 ET

Leerink Partners Maintains Adaptimmune Therapeutics(ADAP.US) With Hold Rating, Maintains Target Price $2

Moomoo NewsAug 13 10:32 ET

Scotiabank Maintains Adaptimmune Therapeutics(ADAP.US) With Buy Rating, Maintains Target Price $3.15

Moomoo NewsAug 13 09:33 ET

A Quick Look at Today's Ratings for Adaptimmune Therapeutics(ADAP.US), With a Forecast Between $1 to $4

Moomoo NewsAug 13 09:00 ET

Scotiabank Sticks to Its Buy Rating for Adaptimmune Therapeutics (ADAP)

TipRanksAug 13 07:27 ET

Buy Rating Affirmed for Adaptimmune Therapeutics Amidst Promising Product Launch and Strong Pipeline

TipRanksAug 13 06:24 ET

Adaptimmune Therapeutics: A Cautious Hold Amid Gradual Launch and Long-Term Growth Strategy

TipRanksAug 13 05:08 ET

Adaptimmune Therapeutics (ADAP) Gets a Sell From Barclays

TipRanksAug 13 04:51 ET